Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar pennysplants (99.60) Submitted: 11/22/2012 7:12:52 PM : Outperform Start Price: $3.22 EXEL Score: -29.74

Reaffirming EXEL as a long speculative holding. Cleaning up after 2 year hiatus from CAPS.

Featured Broker Partners


Advertisement